Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2020

Open Access 01-12-2020 | Idiopathic Pulmonary Fibrosis | Research article

Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database

Authors: Irene Moore, Jeremy Wrobel, Jessica Rhodes, Qi Lin, Susanne Webster, Helen Jo, Lauren Troy, Christopher Grainge, Ian Glaspole, Tamera J. Corte, on behalf of the Australasian ILD Registry

Published in: BMC Pulmonary Medicine | Issue 1/2020

Login to get access

Abstract

Background

Interstitial Lung Disease (ILD) is a group of respiratory conditions affecting the lung interstitium often associated with progressive respiratory failure. There is increasing recognition of the need for improved epidemiological data to help determine best practice and improve standardisation of care. The Australasian ILD Registry (AILDR) is a bi-national registry of patients with all ILD subtypes designed to establish a clinically meaningful database reflecting real world practice in Australasia with an objective to improve diagnostic and treatment pathways through research and collaboration.

Methods

AILDR is a prospective observational registry recruiting patients attending ILD clinics at centres around Australia and New Zealand. Core and non-core data are stored on a secure server. The pilot phase was launched in 2016 consisting of four sites in Australia. Currently in its second phase a further 16 sites have been recruited, including three in New Zealand.

Results

A total of 1061 participants were consented during the pilot phase. Baseline data demonstrated a mean age 68.3 ± 12.5 (SD) years, mean FVC (%predicted) 79.1 ± 20.4 (SD), mean DLCO (%predicted) 58.5 ± 17.9 (SD) and nadir exertional SpO2 (%) 91 ± 6.9 (SD). Idiopathic pulmonary fibrosis (31%) and connective-tissue disease related ILD (21.7%) were the two most common subtypes. Baseline demographics and physiology were not significantly different across the four centres.

Conclusion

AILDR is an important clinical and research tool providing a platform for epidemiological data that will prove essential in promoting understanding of a rare cohort of lung disease and provide foundations for our aspiration to standardise investigation and treatment pathways of ILD across Australasia.
Appendix
Available only for authorised users
Literature
1.
go back to reference Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.CrossRef Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.CrossRef
2.
go back to reference Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.CrossRef Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.CrossRef
3.
go back to reference Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.CrossRef Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.CrossRef
4.
go back to reference The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-Acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–77.CrossRef The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-Acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–77.CrossRef
6.
go back to reference Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–28.CrossRef Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–28.CrossRef
7.
go back to reference Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–27.CrossRef Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–27.CrossRef
8.
go back to reference Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–68.CrossRef Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–68.CrossRef
9.
go back to reference Cottin V, Castillo D, Poletti V, Kreuter M, Corte TJ, Spagnolo P. Should patients with interstitial lung disease be seen by experts? Chest. 2018;154(3):713–4.CrossRef Cottin V, Castillo D, Poletti V, Kreuter M, Corte TJ, Spagnolo P. Should patients with interstitial lung disease be seen by experts? Chest. 2018;154(3):713–4.CrossRef
11.
go back to reference Farrand E, Anstrom KJ, Bernard G, Butte AJ, Iribarren C, Ley B, et al. Closing the evidence gap in interstitial lung disease. The promise of real-world data. Am J Respir Crit Care Med. 2019;199(9):1061–5.CrossRef Farrand E, Anstrom KJ, Bernard G, Butte AJ, Iribarren C, Ley B, et al. Closing the evidence gap in interstitial lung disease. The promise of real-world data. Am J Respir Crit Care Med. 2019;199(9):1061–5.CrossRef
12.
go back to reference Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24(135):58–64.CrossRef Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24(135):58–64.CrossRef
13.
go back to reference Raghu G. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Eur Respir J. 2017;50(4):1701209.CrossRef Raghu G. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Eur Respir J. 2017;50(4):1701209.CrossRef
14.
go back to reference Fisher JH, Kolb M, Algamdi M, et al. Baseline characteristics and co-morbidities in the CAndian REgistry for pulmonary fibrosis. BMC Pulm Med. 2019;19:223.CrossRef Fisher JH, Kolb M, Algamdi M, et al. Baseline characteristics and co-morbidities in the CAndian REgistry for pulmonary fibrosis. BMC Pulm Med. 2019;19:223.CrossRef
15.
go back to reference Flaherty K, De Andrade J, Lancaster L, et al. Baseline characteristics of 1461 participants in the Pulmonary Fibrosis Foundation Patient Registry [abstract]. Eur Respir J. 2018;52(Suppl. 62):PA2199. Flaherty K, De Andrade J, Lancaster L, et al. Baseline characteristics of 1461 participants in the Pulmonary Fibrosis Foundation Patient Registry [abstract]. Eur Respir J. 2018;52(Suppl. 62):PA2199.
16.
go back to reference Kreuter M, Herth FJF, Wacker M, et al. Interims analysis of the EXCITING-ILD registry (registry for exploring clinical and epidemiological characteristics of interstitial lung diseases)[abstract]. Eur Respir J. 2018;52(Suppl. 62):PA2197. Kreuter M, Herth FJF, Wacker M, et al. Interims analysis of the EXCITING-ILD registry (registry for exploring clinical and epidemiological characteristics of interstitial lung diseases)[abstract]. Eur Respir J. 2018;52(Suppl. 62):PA2197.
17.
go back to reference Strambu I, Salmen T, Traila D, et al. Romanian Registry for Interstitial Lung Diseases (REGIS): inclusion of patients in 3 years [abstract]. Eur Respir J. 2017;50:PA868. Strambu I, Salmen T, Traila D, et al. Romanian Registry for Interstitial Lung Diseases (REGIS): inclusion of patients in 3 years [abstract]. Eur Respir J. 2017;50:PA868.
18.
go back to reference Singh S, Collinf BF, Sharma BB, et al. Interstitial lung disease in India: results of a prospective registry. Am J Respir Crit Care Med. 2017;195(6):801–13.CrossRef Singh S, Collinf BF, Sharma BB, et al. Interstitial lung disease in India: results of a prospective registry. Am J Respir Crit Care Med. 2017;195(6):801–13.CrossRef
20.
go back to reference Tinelli C, De Silvestri A, Richeldi L, Oggionni T. The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(Suppl 1):S4–8.PubMed Tinelli C, De Silvestri A, Richeldi L, Oggionni T. The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(Suppl 1):S4–8.PubMed
21.
go back to reference Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece [abstract]. Respir Med. 2009;103(8):1122–9.CrossRef Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece [abstract]. Respir Med. 2009;103(8):1122–9.CrossRef
22.
go back to reference Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150(4):967–72.CrossRef Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150(4):967–72.CrossRef
23.
go back to reference Alhamad EH. Interstitial lung diseases in Saudi Arabia: a single-center study. Ann Thorac Med. 2013 Jan-Mar;8(1):33–7.CrossRef Alhamad EH. Interstitial lung diseases in Saudi Arabia: a single-center study. Ann Thorac Med. 2013 Jan-Mar;8(1):33–7.CrossRef
24.
go back to reference Thomeer M, Demedts M, Vandeurzen K, et al. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. 2001;56(3):163–72.CrossRef Thomeer M, Demedts M, Vandeurzen K, et al. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. 2001;56(3):163–72.CrossRef
25.
go back to reference Hyldgaard C. A cohort study of Danish patients with interstitial lung diseases. lung diseases: Burden, severity, treatment and survival [abstract]. Dan Med J. 2015;62(4):B5069.PubMed Hyldgaard C. A cohort study of Danish patients with interstitial lung diseases. lung diseases: Burden, severity, treatment and survival [abstract]. Dan Med J. 2015;62(4):B5069.PubMed
26.
go back to reference López-Campos JL, Rodríguez-Becerra E, Neumosur Task Group. Incidence of interstitial lung diseases in the south of Spain 1998-2000: the RENIA study. Eur J Epidemiol. 2004;19(2):155–61.CrossRef López-Campos JL, Rodríguez-Becerra E, Neumosur Task Group. Incidence of interstitial lung diseases in the south of Spain 1998-2000: the RENIA study. Eur J Epidemiol. 2004;19(2):155–61.CrossRef
27.
go back to reference Meier FMP, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2012;71:1355–60.CrossRef Meier FMP, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2012;71:1355–60.CrossRef
29.
go back to reference Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, Dawson J, Sathi N, Ahmad Y, Koduri G, Young A, on behalf of the British Rheumatoid Interstitial Lung (BRILL) Network. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics—a large multicentre UK study. Rheumatology. 2014;53(Issue 9):1676–82 https://doi.org/10.1093/rheumatology/keu165.CrossRef Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, Dawson J, Sathi N, Ahmad Y, Koduri G, Young A, on behalf of the British Rheumatoid Interstitial Lung (BRILL) Network. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics—a large multicentre UK study. Rheumatology. 2014;53(Issue 9):1676–82 https://​doi.​org/​10.​1093/​rheumatology/​keu165.CrossRef
Metadata
Title
Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database
Authors
Irene Moore
Jeremy Wrobel
Jessica Rhodes
Qi Lin
Susanne Webster
Helen Jo
Lauren Troy
Christopher Grainge
Ian Glaspole
Tamera J. Corte
on behalf of the Australasian ILD Registry
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2020
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-020-01297-2

Other articles of this Issue 1/2020

BMC Pulmonary Medicine 1/2020 Go to the issue